Crinetics Pharma CFO Schilke sells $266k in stock

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices jump over 4% as Middle East war escalates, fuels supply fears Iran conflict latest: Hegseth says Iran conflict has "only just begun" Gold hands back gains as US dollar rebounds; Middle East war continues Morgan Stanley explains why gold is falling despite Iran escalation (South Africa Philippines Nigeria) Crinetics Pharma CFO Schilke sells $266k in stock By Insider Trading Published 03/05/2026, 02:33 AM Crinetics Pharma CFO Schilke sells $266k in stock 0 CRNX -1.52% Crinetics Pharmaceuticals NASDAQ:CRNX Chief Financial Officer Tobin Schilke sold 6,713 shares of common stock on March 3, 2026, at an average price of $39.67, for a total transaction value of $266,304. Prices ranged from $39.67 to $39.74.The transaction comes as the stock trades at $39.51, with shares down nearly 10% over the past week. According to InvestingPro analysis, the company appears undervalued at current levels, with the $4.14 billion biotech firm showing positive analyst sentiment. Following the transaction, Schilke directly owns 78,121 shares of Crinetics Pharmaceuticals. The sale was to cover tax obligations related to the vesting of restricted stock units granted on March 10, 2025, and was executed under a pre-arranged Rule 10b5-1 trading plan. In other recent news, Crinetics Pharmaceuticals reported its financial results for the fourth quarter of 2025, exceeding market expectations. The company achieved an actual earnings per share of -$1.29, which was better than the forecasted EPS of -$1.34. Revenue also surpassed estimates, reaching $6.1 million compared to the anticipated $4 million. Additionally, Citizens lowered its price target on Crinetics Pharmaceuticals shares to $96 from $105, while maintaining a Market Outperform rating. This decision was based on early launch metrics for Palsonify, which indicate strong potential for the drug’s adoption in treating acromegaly. Physicians surveyed expect a 20% to 30% adoption ...